Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

This study is testing a combination of two drugs — penpulimab (an immunotherapy) and cetuximab (a targeted therapy) — as a first-line treatment for people with head and neck cancer that has come back or spread to other parts of the body and cannot be treated with surgery or radiation. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with squamous cell carcinoma of the head and neck (mouth, throat, voice box, or lower throat region) - Your cancer has returned or spread and cannot be treated with surgery or radiation - Your tumor tests positive for PD-L1 (a marker your doctor can check) - You have at least one measurable tumor - You are in good physical condition (ECOG 0 or 1) and expected to live at least 3 more months **You may NOT be eligible if...** - You have received prior systemic treatment for recurrent or metastatic disease - You have serious heart, liver, or blood count problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.